News | April 19, 2025
GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Experts urge early detection & better access to care
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
